The estimated Net Worth of David J Woodhouse is at least $2.12 Million dollars as of 29 December 2021. Mr. Woodhouse owns over 17,654 units of Ngm Biopharmaceuticals Inc stock worth over $27,187 and over the last 5 years he sold NGM stock worth over $0. In addition, he makes $2,092,150 as Chief Executive Officer und Director at Ngm Biopharmaceuticals Inc.
David has made over 2 trades of the Ngm Biopharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 17,654 units of NGM stock worth $138,054 on 29 December 2021.
The largest trade he's ever made was exercising 17,654 units of Ngm Biopharmaceuticals Inc stock on 29 December 2021 worth over $138,054. On average, David trades about 3,628 units every 5 days since 2020. As of 29 December 2021 he still owns at least 17,654 units of Ngm Biopharmaceuticals Inc stock.
You can see the complete history of Mr. Woodhouse stock trades at the bottom of the page.
David J. Woodhouse Ph.D. has been appointed as Chief Executive Officer, Director of the Company effective 7/13/2020. Mr. Woodhouse became our Chief Executive Officer, Acting Chief Financial Officer and a member of our Board of Directors in September 2018, after having served as our Chief Financial Officer from March 2015 until September 2018. From 2002 to 2015, he was an investment banker at Goldman Sachs & Co. LLC, most recently as a managing director in the healthcare investment banking group and co-head of biotechnology investment banking. Earlier in his career, Dr. Woodhouse worked at Dynavax Technologies and also as a research assistant at Amgen, Inc. Dr. Woodhouse received a B.A. in pharmacology from the University of California, Santa Barbara, an M.B.A. from the Tuck School of Business at Dartmouth and a Ph.D. in molecular pharmacology from Stanford University School of Medicine.
As the Chief Executive Officer und Director of Ngm Biopharmaceuticals Inc, the total compensation of David Woodhouse at Ngm Biopharmaceuticals Inc is $2,092,150. There are no executives at Ngm Biopharmaceuticals Inc getting paid more.
David Woodhouse is 50, he's been the Chief Executive Officer und Director of Ngm Biopharmaceuticals Inc since 2020. There are 13 older and 4 younger executives at Ngm Biopharmaceuticals Inc. The oldest executive at Ngm Biopharmaceuticals Inc is David Goeddel, 68, who is the Lead independent director.
David's mailing address filed with the SEC is C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Ngm Biopharmaceuticals Inc have traded over $9,159,599 worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth $177,396,366 . The most active insiders traders include Peter Svennilson, David V Goeddel und Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $171,092. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth $15,615.
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include: